PCSK9 and type 2 diabetes mellitus: Leveraging the data collected from a large study conducted in ~ 281,000 patients with T2D between 2015 and 2016, we found that among ~ 100,000 subjects with data on LLT, 61% were treated with statins (with an additional 1.2% in ezetimibe alone) PCSK9 inhibitors were reimbursed by Italian national health systems since 2017.